Our cationic poloxamers patent is now granted in Australia

BLOG > News & Events > Our cationic poloxamers patent is now granted in Australia

Cationic poloxamers and their use in transduction

Another milestone for our transduction enhancer patent portfolio.

We are pleased to announce that our patent on modified poloxamers has now been granted in Australia.

Patent No. AU2020314617, “CATIONIC POLOXAMERS AND THEIR USE IN TRANSDUCTION,” covers our method for synthetically modifying poloxamers to confer additional biological properties, including their association with viral vectors such as lentivirus, AAV and adenovirus, as well as magnetic nanoparticles.

The patent covers the synthesis and use of several of our products, including LentiBlast™ Premium, AAVBlast™, ViroMag™ Stem and ViroMICST™ Stem.

This further expands our international intellectual property protection for our transduction enhancer technologies and strengthens our position in a strategic market.

A significant step forward as we continue to advance and protect our innovative technologies in cell and gene therapy.

Related publications

Partnership Opportunities

As new R&D programs take shape and funding opportunities emerge, we would like to highlight that we’re open to multiple collaboration models.
Read more

New Distribution Partnership

We’re thrilled to welcome Bio Medical Scientific Services LLC as our newest distribution partner!
Read more

New partnership with ExploRNA Therapeutics to strengthen our mRNA platform

This partnership marks an important milestone in strengthening our RNA platform and expanding high-performance solutions for the mRNA community.
Read more